Healthcare Realty Trust Inc. - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026, for Healthcare Realty Trust Inc. (HR), a real estate investment trust (REIT) focused on outpatient healthcare properties. As of the reporting date, the Company owned or held interests in approximately 501 consolidated properties totaling roughly 28.9 million square feet across 26 states. The Company operates as an umbrella partnership REIT, with 98.8% ownership of the Operating Partnership (OP).
Key Financial Metrics
| Metric (in thousands, except per share) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $281,849 | $560,839 |
| Net Loss (GAAP) | $(43,955) | $(43,934) |
| Net Loss Attributable to Common Stockholders | $(43,514) | $(43,570) |
| Funds From Operations (FFO) | $126,142 | $249,840 |
| Normalized FFO | $143,703 | $288,085 |
| Funds Available for Distribution (FAD) | $109,360 | $222,218 |
| Cash Flow from Operating Activities | N/A | $195,063 |
| Total Debt (Notes and Bonds Payable) | $4,166,944 | $4,166,944 |
| Cash and Cash Equivalents | $18,987 | $18,987 |
| Dividends Declared (per share) | $0.24 | $0.48 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 5.3% year-over-year for the quarter and 6.0% for the six-month period. Rental income dropped $16.5 million (Q2) and $37.8 million (YTD), primarily due to property dispositions in 2025 and 2026, partially offset by leasing activity.
- Improved Net Loss: GAAP net loss improved significantly from $(160.1) million in Q2 2025 to $(44.0) million in Q2 2026. This improvement was driven by a substantial reduction in impairment charges (from $142.3 million to $42.7 million) and lower interest expense.
- Expense Reduction: General and administrative expenses fell 38.8% in Q2 2026 compared to the prior year, largely due to a decrease in restructuring and severance charges. Property operating expenses also declined 5.0% due to dispositions.
- Debt Restructuring: The Company issued $700 million in 3.00% 2032 Exchangeable Senior Notes in May 2026, using proceeds to repay $600 million of Senior Notes due in August 2026. Additionally, a $400 million Delayed Draw Term Loan facility was established but remains undrawn.
Outlook, Risks, and Unusual Items
- Impairment Charges: The Company recognized $42.7 million in real estate impairments for the quarter, primarily related to properties sold or with changed holding periods. This is a significant decrease from the $142.3 million recorded in the same period last year.
- Capital Markets Activity: The Company repurchased approximately 3.8 million shares of common stock in Q2 2026 for $75.0 million, approved in connection with the 2032 Exchangeable Senior Notes issuance. Approximately $400.1 million remains under the current repurchase authorization.
- Liquidity: As of June 30, 2026, the Company had approximately $1.6 billion available under its Revolving Facility and Delayed Draw Term Loan, net of commercial paper borrowings, alongside $19.0 million in cash.
- Risk Factors: Key risks include tenant concentration (reliance on health systems), potential for further impairment charges, interest rate volatility, and the impact of the "One Big Beautiful Bill Act" passed in 2025 on healthcare demand. The Company also faces risks related to purchase options on properties, which could limit reinvestment returns.
- Lease Expirations: Approximately 10-15% of leases are expected to expire annually. For the remainder of 2026, 329 leases totaling 0.9 million square feet are set to expire.
Investor Verification Checklist
- Impairment Drivers: Verify the specific properties triggering the $42.7 million impairment charge and the assumptions used in fair value modeling.
- Debt Maturity Profile: Confirm the weighted average cost of debt and the impact of the new 2032 Exchangeable Senior Notes on future interest expense and potential dilution.
- Occupancy and Leasing: Review the 92.6% occupancy rate for same-store properties and the success rate of re-leasing expiring space, particularly given the 10-15% annual expiration rate.
- FFO vs. GAAP Reconciliation: Analyze the significant difference between GAAP net loss and FFO/Normalized FFO to understand the sustainability of cash flow generation.
- Share Repurchase Impact: Assess the remaining $400 million repurchase authorization and its potential effect on share count and earnings per share in future periods.